Chargement en cours...
A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
PURPOSE: The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients. PATIENTS AND METHODS: CPR analysis was conducted from a US payer perspective over 24 weeks for early moderate-to-severe ser...
Enregistré dans:
| Publié dans: | Clinicoecon Outcomes Res |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7571575/ https://ncbi.nlm.nih.gov/pubmed/33116698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S263903 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|